Vikram Purohit
Stock Analyst at Morgan Stanley
(1.63)
# 3,332
Out of 5,182 analysts
163
Total ratings
24.24%
Success rate
-9.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Maintains: Overweight | $18 → $16 | $5.79 | +176.34% | 4 | Mar 25, 2026 | |
| INCY Incyte | Maintains: Equal-Weight | $92 → $94 | $95.93 | -2.01% | 26 | Jan 6, 2026 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $31 → $34 | $21.46 | +58.43% | 3 | Oct 28, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $80 → $79 | $64.49 | +22.50% | 11 | Oct 20, 2025 | |
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $3.06 | +92.48% | 3 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $3.11 | +60.77% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $229.25 | +9.05% | 19 | May 5, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $168.51 | +12.76% | 19 | Feb 27, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.93 | +82.56% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $27.50 | +12.73% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $16 | $118.37 | -86.48% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $23.63 | -57.68% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $8.53 | +392.38% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $85.40 | -51.99% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $8.06 | +396.28% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $1.90 | +584.21% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $11.58 | +228.15% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $5.41 | +269.69% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $16.02 | -37.58% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.01 | +2,078.22% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $21.04 | -4.94% | 2 | Aug 5, 2020 |
COMPASS Pathways
Mar 25, 2026
Maintains: Overweight
Price Target: $18 → $16
Current: $5.79
Upside: +176.34%
Incyte
Jan 6, 2026
Maintains: Equal-Weight
Price Target: $92 → $94
Current: $95.93
Upside: -2.01%
Zenas BioPharma
Oct 28, 2025
Maintains: Overweight
Price Target: $31 → $34
Current: $21.46
Upside: +58.43%
Halozyme Therapeutics
Oct 20, 2025
Maintains: Overweight
Price Target: $80 → $79
Current: $64.49
Upside: +22.50%
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $3.06
Upside: +92.48%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $3.11
Upside: +60.77%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $229.25
Upside: +9.05%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $168.51
Upside: +12.76%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.93
Upside: +82.56%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $27.50
Upside: +12.73%
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $118.37
Upside: -86.48%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $23.63
Upside: -57.68%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $8.53
Upside: +392.38%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $85.40
Upside: -51.99%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $8.06
Upside: +396.28%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $1.90
Upside: +584.21%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $11.58
Upside: +228.15%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $5.41
Upside: +269.69%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $16.02
Upside: -37.58%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.01
Upside: +2,078.22%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $21.04
Upside: -4.94%